This week of activity for Medtronic (Minneapolis) has been the equivalent of taking two steps forward and then one giant step back. On Monday the med-tech powerhouse reported that it would be shelling out $1.025 billion to snag CoreValve (Irvine, California) and Ventor Technologies (Netanya, Israel) to expand its cardiovascular business. (Medical Device Daily)

Newly released results of a trial that compares the impact of coronary-artery bypass graft surgery (CABG) and percutaneous coronary intervention (PCI) show that patients who underwent the former have fewer adverse effects than those who underwent the latter. (Medical Device Daily)

Avantis Medical Systems (Sunnyvale, California) is getting a better view when it comes down to properly finding tumors during colonoscopies. And the company literally means that. (Medical Device Daily)